Pfizer and the Economics of the Pharmaceutical Oligopoly
This paper examines the economics of the pharmaceutical industry through the lens of Pfizer Incorporated, one of the sector's dominant firms. It explores the inelastic nature of demand for prescription drugs, the oligopolistic market structure that characterizes the industry, and the barriers to entry that protect established players. The paper discusses how Pfizer competes through patent protection, brand recognition, and research and development investment, using Viagra as a key case study. It also addresses the impact of generic competition under the Hatch-Waxman Act, drug pricing dynamics across markets, and the cost structures that give major pharmaceutical firms lasting price-setting power.
- Introduction: Pfizer's Market Position: Overview of Pfizer's global operations and products
- Inelastic Demand for Pharmaceutical Products: Why drug demand resists price changes
- The Pharmaceutical Industry as an Oligopoly: Few firms control pharmaceutical market pricing
- Competition, Pricing, and Market Power: How Pfizer competes and maintains price control
- Research and Development Costs and Resources: R&D intensity and cost of new drug development
- Generic Competition and Price Dynamics: Hatch-Waxman Act effects on pricing and innovation
- Conclusion: Sources of Pfizer's Price-Setting Power: Patents, R&D, and brand drive Pfizer's pricing power
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Uses a real-world company (Pfizer) as a concrete anchor for abstract economic concepts such as oligopoly, inelastic demand, and price-setting power, making theory immediately tangible.
- Draws on multiple source types — industry association data, academic research, and the company's own official communications — to support its economic analysis.
- Effectively contrasts products within the same company (Viagra vs. Sudafed) to illustrate that demand elasticity varies even within a single firm's portfolio.
Key academic technique demonstrated
The paper demonstrates applied economic analysis: it takes standard microeconomic frameworks (oligopoly structure, barriers to entry, price interdependence) and applies them systematically to a real industry and company. Each theoretical claim is followed by a specific example — such as patent protection over Viagra or the Hatch-Waxman Act's effect on generic entry — which grounds the argument in observable market behavior.
Structure breakdown
The paper is organized as a question-and-answer framework, with each section addressing a distinct economic question about Pfizer and the pharmaceutical industry. It moves logically from company background and demand characteristics, through market structure and competitive dynamics, to cost analysis and price-setting power. This scaffolded structure suits an economics case study format well, guiding the reader through layered concepts in a clear sequence.
Introduction: Pfizer's Market Position
According to its official website, Pfizer Incorporated "discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. Our innovative, value-added products improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has three business segments: health care, animal health, and consumer health care. Our products are available in more than one hundred and fifty countries." (Official Website, 2004)
Although Pfizer's claims to offer value to its consumers may be debatable, its position as the industry leader in sheer dollar terms cannot be disputed. Of particular value to Pfizer as a publicly traded company has been its patent on the drug Viagra, and it continues to capitalize upon its dominance as an industry leader — even in the section of its website designed to attract prospective employees.
Inelastic Demand for Pharmaceutical Products
Demand for pharmaceuticals is relatively inelastic across the industry as a whole — not simply for Pfizer's drugs. Few consumers can say, "The economy is bad and my budget is tight, so I'll cut back on my insulin, beta blockers, or cholesterol-lowering drug this month." However, generic alternatives have posed potent competitive threats for the industry (EGA, 2004).
Furthermore, although Pfizer has the advantage of holding certain drugs — such as Viagra — whose brand names are virtually synonymous with their function, Viagra is not a life-preserving drug in the way that many prescription medications are. Its sexual enhancement function places it in a different category of necessity. Nevertheless, the potency of the Viagra name should not be underestimated. Much like Eli Lilly's relationship with the antidepressant Prozac before its patent expired, consumers recognize Viagra's function as synonymous with the brand rather than with any generic alternative.
Prozac, a potent antidepressant, was far more necessary to its core audience of psychologically affected users than Viagra, though Prozac was also described by some physicians as a "cosmetic" drug. The comparison illustrates that even within the category of relatively inelastic demand, the degree of necessity — and therefore the vulnerability to generic substitution — varies considerably among pharmaceutical products.
Works Cited
Danizon, Patricia. (2002). "Parallel Trade and Competitive Pricing of Medicine." Retrieved July 15, 2004, from http://www.pfizerforum.com/english/danzon.shtml
EGA: European Generic Drug Association. (2004). Retrieved July 15, 2004, from
Investopedia. (2004). "Monopolies, Oligopolies, and Perfect Competition." http://www.investopedia.com/university/economics/economics6.asp
Pfizer. (2004). "About Us." Official Website. Retrieved July 15, 2004, from
Pfizer. (2004). "Increased Incidents of Pharmaceutical Counterfeiting Threaten Patient Safety; the Time to Act Is Now." Official Website. Retrieved July 15, 2004, from
Create your account
Always verify citation format against your institution’s current style guide requirements.